TDP-43 Proteinopathies Market

Market Overview:

The 7 major TDP-43 proteinopathies markets reached a value of US$ 661.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 925.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.09% during 2024-2034.

The TDP-43 proteinopathies market has been comprehensively analyzed in IMARC's new report titled "TDP-43 Proteinopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". TDP-43 proteinopathies are a group of neurodegenerative disorders characterized by the irregular accumulation of a protein called TAR DNA-binding protein 43 (TDP-43) in the brain and spinal cord. This protein is mainly essential for RNA processing and regulation, but in these diseases, it becomes abnormally modified and forms aggregates within neurons. The common symptoms associated with TDP-43 proteinopathies include changes in thinking, memory, and behavior, muscle weakness, atrophy, twitching, difficulties with movement control, language, and speech problems, apathy, disinhibition, social withdrawal, etc. Individuals suffering from these ailments may also experience trouble performing daily activities, such as dressing, eating, bathing, using tools or objects, etc. The diagnosis of TDP-43 proteinopathies typically involves a combination of clinical evaluation, medical history review, and pathological examination. Various neuroimaging techniques, like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, may be performed to assess brain structure and function. These studies can help to identify patterns of atrophy or abnormal metabolic activity that are associated with the conditions. Furthermore, the healthcare provider may recommend an analysis of cerebrospinal fluid to measure protein levels and confirm a diagnosis.

The increasing cases of genetic mutations, which can lead to abnormal aggregation and accumulation of proteins within the body, are primarily driving the TDP-43 proteinopathies market. Besides this, the rising geriatric population, who are susceptible to age-related cellular and molecular changes, such as impaired protein homeostasis and enhanced oxidative stress, is creating a positive outlook for the market. Moreover, the widespread adoption of various medications, including antipsychotics, antidepressants, sleep aids, etc., which work by targeting specific neurotransmitter systems in the brain to alleviate disease symptoms and restore cognitive abilities in patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, such as canes, walkers, wheelchairs, etc., since they help to reduce mobility impairments, maintain independence, and improve daily functioning, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of small molecule therapeutics that can specifically target the pathological processes associated with the condition, thereby decreasing the formation of abnormal protein aggregates, is expected to drive the TDP-43 proteinopathies market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the TDP-43 proteinopathies market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for TDP-43 proteinopathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the TDP-43 proteinopathies market in any manner.

Recent Developments:

• In June 2024, Mitsubishi Tanabe Pharma America reported the final results of the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in amyotrophic lateral sclerosis (ALS). Final results showed that the daily dose regimen of RADICAVA ORS (edaravone) did not outperform the FDA-approved on/off dosing regimen at 48 weeks in terms of the primary endpoint of Combined Assessment of Function and Survival (CAFS). Both dosage regimens produced a comparable change in ALSFRS-R from baseline to week 48.
• In February 2024, Biogen Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY for the treatment of adults with amyotrophic lateral sclerosis caused by a mutation in the superoxide dismutase 1 (SOD1) gene.
• In September 2023, AcuraStem stated that it had signed a license agreement with Takeda to develop and market its PIKFYVE targeted medicines, including AS-202, a novel antisense oligonucleotide for the treatment of ALS.

Key Highlights:

• Patients with spontaneous amyotrophic lateral sclerosis (up to 97%) and frontotemporal lobar degeneration (~45%) have TDP-43 positive neuronal inclusions, indicating a function for this protein in disease development.
• ALS is a group of proteinopathies that cause neuronal death and high levels of NFTs (hyperphosphorylated tau, α-synuclein, and TDP-43).
• The average age of ALS onset is 58-60 years, and patients typically live for 2-5 years after symptoms appear.
• ALS is more frequent in males than in women, and the frequency of new cases rises with age until around 80.
• However, ALS can occasionally emerge in persons in their 20s and 30s.

Drugs:

Qalsody (Tofersen) is an antisense oligonucleotide (ASO) that binds to SOD1 mRNA, reducing SOD1 protein synthesis. This drug was given fast approval by the U.S. Food and Drug Administration to treat adult patients with amyotrophic lateral sclerosis who had a mutation in the SOD1 gene.

ABBV-CLS-7262 is a small molecule drug that activates the eukaryotic initiation factor EIF2b, which starts protein synthesis from mRNA. Restored EIF2b activity has been found to protect against neurodegeneration in preclinical models of prion disease, frontotemporal dementia, and ALS.

Ibudilast is a first-in-class, orally accessible small molecule glial attenuator that lowers pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 while potentially upregulating anti-inflammatory cytokine IL-10. It has also been demonstrated to be a functional antagonist of the toll-like receptor 4 (TLR4), which may contribute to its neuroinflammation inhibition.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the TDP-43 proteinopathies market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the TDP-43 proteinopathies market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current TDP-43 proteinopathies marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the TDP-43 proteinopathies market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the TDP-43 proteinopathies market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the TDP-43 proteinopathies market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies across the seven major markets?
• What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with TDP-43 proteinopathies across the seven major markets?
• What is the size of the TDP-43 proteinopathies patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of TDP-43 proteinopathies?
• What will be the growth rate of patients across the seven major markets?
   

TDP-43 Proteinopathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for TDP-43 proteinopathies drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the TDP-43 proteinopathies market?
• What are the key regulatory events related to the TDP-43 proteinopathies market?
• What is the structure of clinical trial landscape by status related to the TDP-43 proteinopathies market?
• What is the structure of clinical trial landscape by phase related to the TDP-43 proteinopathies market?
• What is the structure of clinical trial landscape by route of administration related to the TDP-43 proteinopathies market?